Population pharmacokinetics of olprinone in healthy male volunteers

Código QR

Population pharmacokinetics of olprinone in healthy male volunteers

Takayuki Kunisawa,1 Hidefumi Kasai,2 Makoto Suda,2 Manabu Yoshimura,3 Ami Sugawara,3 Yuki Izumi,3 Takafumi Iida,3 Atsushi Kurosawa,3 Hiroshi Iwasaki3 1Surgical Operation Department, Asahikawa Medical University Hospital, Hokkaido, Japan; 2Clinical Study Management Division, Bell Medical Solutions I...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kunisawa T, Kasai H, Suda M, Yoshimura M, Sugawara A, Izumi Y, Iida T, Kurosawa A, Iwasaki H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/00566222cb6d4f0dab4aaa3c70fac0c1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers
por: Nagelschmitz J, et al.
Publicado: (2014)

Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteers
por: Farr SJ, et al.
Publicado: (2015)

Effect of food on the pharmacokinetics of dronabinol oral solution versus dronabinol capsules in healthy volunteers
por: Oh DA, et al.
Publicado: (2017)

A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males
por: Kalman DS, et al.
Publicado: (2015)

Serum Predose Metabolic Profiling for Prediction of Rosuvastatin Pharmacokinetic Parameters in Healthy Volunteers
por: Anne Michelli Reis Silveira, et al.
Publicado: (2021)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects
por: Cui Y, et al.
Publicado: (2013)

Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
por: Cui Y, et al.
Publicado: (2014)

Lack of effect of ezogabine/retigabine on the pharmacokinetics of digoxin in healthy individuals: results from a drug–drug interaction study
por: Tompson DJ, et al.
Publicado: (2014)

PK/PD modeling of FXI antisense oligonucleotides to bridge the dose‐FXI activity relation from healthy volunteers to end‐stage renal disease patients
por: Stefan Willmann, et al.
Publicado: (2021)

A population pharmacokinetic‐pharmacodynamic model of YH12852, a highly selective 5‐hydroxytryptamine 4 receptor agonist, in healthy subjects and patients with functional constipation
por: Siun Kim, et al.
Publicado: (2021)

Metabolism and Excretion of Intravenous, Radio-Labeled Amisulpride in Healthy, Adult Volunteers
por: Fox GM, et al.
Publicado: (2019)

Effects of a reactive oxygen species generator, napabucasin (BBI608), on tolerability, safety, pharmacokinetics, and QT/QTc interval in healthy volunteers
por: Naoto Noda, et al.
Publicado: (2021)

Bioavailability of everolimus administered as a single 5 mg tablet versus five 1 mg tablets: a randomized, open-label, two-way crossover study of healthy volunteers
por: Thudium K, et al.
Publicado: (2015)

Bioavailability study of dronabinol oral solution versus dronabinol capsules in healthy volunteers
por: Parikh N, et al.
Publicado: (2016)

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
por: Sejung Hwang, et al.
Publicado: (2021)

Pharmacokinetics and skin-tissue penetration of daptomycin in rats
por: Matsumoto K, et al.
Publicado: (2015)

Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers
por: Jakate A, et al.
Publicado: (2019)

Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors
por: Persson PB
Publicado: (2015)

A Phase 1, randomized, open-label crossover study to evaluate the safety and pharmacokinetics of 400 mg albaconazole administered to healthy participants as a tablet formulation versus a capsule formulation
por: van Rossem K, et al.
Publicado: (2013)

Pharmacokinetic equivalence study of two formulations of the anticonvulsant pregabalin
por: Tjandrawinata RR, et al.
Publicado: (2015)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
por: Frost C, et al.
Publicado: (2014)

Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma
por: Li Zhang, et al.
Publicado: (2021)

The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects
por: Frost C, et al.
Publicado: (2017)

A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban [Corrigendum]
por: Frost C, et al.
Publicado: (2018)

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
por: Xia Pu, et al.
Publicado: (2021)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model
por: Lozano R, et al.
Publicado: (2013)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti VV, et al.
Publicado: (2013)

Distribution of pomalidomide into semen of healthy male subjects after multiple doses
por: Li Y, et al.
Publicado: (2018)

Atazanavir–bilirubin interaction: a pharmacokinetic–pharmacodynamic model [Corrigendum]
por: Lozano R, et al.
Publicado: (2013)

Development of physiologically‐based pharmacokinetic models for standard of care and newer tuberculosis drugs
por: Helen Humphries, et al.
Publicado: (2021)

Absence of effect of steady state bempedoic acid on cardiac repolarization: Results of a thorough QT/QTc study in healthy volunteers
por: Benny M. Amore, et al.
Publicado: (2021)

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
por: Ekaterina Gibiansky, et al.
Publicado: (2021)

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects
por: Frost C, et al.
Publicado: (2018)

Population Pharmacokinetic Model of Plasma and Cellular Mycophenolic Acid in Kidney Transplant Patients from the CIMTRE Study
por: François Riglet, et al.
Publicado: (2020)

ModVizPop: A shiny interface for empowering teams to perform interactive pharmacokinetic/pharmacodynamic simulations
por: Pavan Vaddady, et al.
Publicado: (2021)

Enantiomer-selective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms
por: Hermann R, et al.
Publicado: (2014)

Population pharmacokinetics of belantamab mafodotin, a BCMA‐targeting agent in patients with relapsed/refractory multiple myeloma
por: Chetan Rathi, et al.
Publicado: (2021)

Pharmacokinetic evaluation of D-ribose after oral and intravenous administration to healthy rabbits
por: Alzoubi KH, et al.
Publicado: (2018)

Data driven evaluation of healthy volunteer characteristics at screening for phase I clinical trials to inform on study design and optimize screening processes
por: Annemie Deiteren, et al.
Publicado: (2021)

Development of best practices in physiologically based pharmacokinetic modeling to support clinical pharmacology regulatory decision‐making—A workshop summary
por: Daphney Jean, et al.
Publicado: (2021)